MM+M Podcast 2.28.22: How patients are upending the rare disease paradigm

Investors poured almost $23 billion into rare disease therapeutics development last year, a 28% increase over 2020. Patients have been the spark plug behind the robust funding for, and greater attention around, these drugs. Craig Martin, CEO of rare disease advocacy group Global Genes, explains the perils and pitfalls to this patient-led revolution. Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in
medical marketing, subscribe here.
Music: “Deep Reflection” by DP and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com
for information about our collection and use of personal data for
advertising.